Follicular lymphoma future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Follicular lymphoma}} | {{Follicular lymphoma}} | ||
{{CMG}}; {{AE}} {{AS}} | |||
==Overview== | |||
There are a large number of recent and current clinical trials for follicular lymphoma. Personalised idiotype vaccines have shown promise, but have still to prove their efficacy in randomized clinical trials. | |||
==Future or Investigational therapies== | |||
Personalised idiotype vaccines have shown promise, but have still to prove their efficacy in randomized clinical trials.<ref>{{cite journal |author=Inoges S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M |title=Idiotype vaccines for human B-cell malignancies |journal=Curr. Pharm. Des. |volume=16 |issue=3 |pages=300–7 |date=January 2010 |pmid=20109139 |doi= 10.2174/138161210790170111|url=http://www.benthamdirect.org/pages/content.php?CPD/2010/00000016/00000003/0006B.SGM}}</ref> | |||
In 2010 [[Rituximab]] was approved by the EC for first-line maintenance treatment of follicular lymphoma.<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/ |title=Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy |date=October 29, 2010 }}</ref> Pre-clinical evidence suggests that rituximab could be also used in combination with integrin inhibitors to overcome the resistance to rituximab mediated by stromal cells .<ref>{{Cite journal | last1 = Mraz | first1 = M. | last2 = Zent | first2 = C. S. | last3 = Church | first3 = A. K. | last4 = Jelinek | first4 = D. F. | last5 = Wu | first5 = X. | last6 = Pospisilova | first6 = S. | last7 = Ansell | first7 = S. M. | last8 = Novak | first8 = A. J. | last9 = Kay | first9 = N. E. | last10 = Witzig | doi = 10.1111/j.1365-2141.2011.08794.x | first10 = T. E. | last11 = Nowakowski | first11 = G. S. | title = Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance | journal = British Journal of Haematology | volume = 155 | issue = 1 | pages = 53–64 | year = 2011 | pmid = 21749361 | pmc = }}</ref> However, follicular lymphoma which is CD20 negative will not benefit from Rituximab which targets CD20. | |||
Trial results released in June 2012 show that [[bendamustine]], a drug first developed in East Germany in the 1960s, more than doubled disease progression-free survival when given along with [[rituximab]]. The combination also left patients with fewer side effects than the older treatment (a combination of five drugs—rituximab, cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine and prednisone, collectively called [[R-CHOP]]).<ref>{{cite news |url=http://health.usnews.com/health-news/news/articles/2012/06/03/rediscovered-lymphoma-drug-helps-double-survival-study|title='Rediscovered' Lymphoma Drug Helps Double Survival: Study |date=June 3, 2012 }}</ref> | |||
There are a large number of recent and current clinical trials for follicular lymphoma.<ref>http://clinicaltrials.gov/ct2/results?term=follicular+lymphoma</ref> | |||
==References== | ==References== | ||
{{ | {{reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
Revision as of 20:19, 25 August 2015
|
Follicular lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Follicular lymphoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Follicular lymphoma future or investigational therapies |
|
FDA on Follicular lymphoma future or investigational therapies |
|
CDC on Follicular lymphoma future or investigational therapies |
|
Follicular lymphoma future or investigational therapies in the news |
|
Blogs on Follicular lymphoma future or investigational therapies |
|
Risk calculators and risk factors for Follicular lymphoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
There are a large number of recent and current clinical trials for follicular lymphoma. Personalised idiotype vaccines have shown promise, but have still to prove their efficacy in randomized clinical trials.
Future or Investigational therapies
Personalised idiotype vaccines have shown promise, but have still to prove their efficacy in randomized clinical trials.[1]
In 2010 Rituximab was approved by the EC for first-line maintenance treatment of follicular lymphoma.[2] Pre-clinical evidence suggests that rituximab could be also used in combination with integrin inhibitors to overcome the resistance to rituximab mediated by stromal cells .[3] However, follicular lymphoma which is CD20 negative will not benefit from Rituximab which targets CD20.
Trial results released in June 2012 show that bendamustine, a drug first developed in East Germany in the 1960s, more than doubled disease progression-free survival when given along with rituximab. The combination also left patients with fewer side effects than the older treatment (a combination of five drugs—rituximab, cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine and prednisone, collectively called R-CHOP).[4]
There are a large number of recent and current clinical trials for follicular lymphoma.[5]
References
- ↑ Inoges S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M (January 2010). "Idiotype vaccines for human B-cell malignancies". Curr. Pharm. Des. 16 (3): 300–7. doi:10.2174/138161210790170111. PMID 20109139.
- ↑ "Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy". October 29, 2010.
- ↑ Mraz, M.; Zent, C. S.; Church, A. K.; Jelinek, D. F.; Wu, X.; Pospisilova, S.; Ansell, S. M.; Novak, A. J.; Kay, N. E.; Witzig, T. E.; Nowakowski, G. S. (2011). "Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance". British Journal of Haematology. 155 (1): 53–64. doi:10.1111/j.1365-2141.2011.08794.x. PMID 21749361.
- ↑ "'Rediscovered' Lymphoma Drug Helps Double Survival: Study". June 3, 2012.
- ↑ http://clinicaltrials.gov/ct2/results?term=follicular+lymphoma